Advanced BioMedical Technologies(ABMT)
$0.040.00 (0.00%)
ABMT
Advanced BioMedical Technologies financials statements
$0.04
At close:0.00 (0.00%)
Advanced BioMedical Technologies (ABMT) Ratios
10 Followers
Advanced BioMedical Technologies Ratios
ABMT's free cash flow for Q3 2022 was $-170.31K. For the 2022 fiscal year, ABMT's free cash flow was increased by $0.00 and operating cash flow was $-170.31K. See a summary of the company’s cash flow.
| Ratios | Oct 22 | Oct 21 | Oct 20 | Oct 19 | Oct 18 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.04 | 0.03 | 0.04 | 0.02 | 0.01 |
| Quick Ratio | 0.01 | 0.01 | 0.03 | 0.01 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 |
| Solvency Ratio | -0.06 | -0.08 | -0.08 | -0.14 | -0.16 |
| Operating Cash Flow Ratio | -0.09 | -0.10 | 0.08 | -0.11 | -0.14 |
| Short-Term Operating Cash Flow Coverage | -0.11 | -0.12 | 0.14 | -0.15 | -0.19 |
| Net Current Asset Value | $ -8.04M | $ -8.53M | $ -7.54M | $ -6.58M | $ -5.72M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 17.21 | 15.36 | 10.10 | 22.50 | 30.38 |
| Debt-to-Equity Ratio | -0.86 | -0.82 | -0.64 | -0.76 | -0.77 |
| Debt-to-Capital Ratio | -6.05 | -4.61 | -1.78 | -3.15 | -3.34 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.05 | -0.05 | -0.06 | -0.03 | -0.03 |
| Debt Service Coverage Ratio | -0.02 | -0.05 | -0.06 | -0.11 | -0.14 |
| Interest Coverage Ratio | -0.54 | -1.23 | -1.36 | -1.85 | -2.11 |
| Debt to Market Cap | 1.93 | 1.40 | 0.45 | 1.18 | 0.30 |
| Interest Debt Per Share | 0.10 | 0.10 | 0.07 | 0.08 | 0.07 |
| Net Debt to EBITDA | -41.00 | -18.65 | -16.06 | -8.17 | -6.79 |
| Profitability Margins | |||||
| Gross Profit Margin | 81.88% | 54.50% | 58.07% | 34.84% | 0.00% |
| EBIT Margin | -68.23% | -238.75% | -277.59% | -5339.37% | 0.00% |
| EBITDA Margin | -61.26% | -214.63% | -228.74% | -5157.97% | 0.00% |
| Operating Profit Margin | -66.38% | -230.65% | -361.38% | -5187.77% | 0.00% |
| Pretax Profit Margin | -190.22% | -426.10% | -543.75% | -8139.49% | 0.00% |
| Net Profit Margin | -190.22% | -426.10% | -543.75% | -8139.49% | 0.00% |
| Continuous Operations Profit Margin | -190.22% | -426.10% | -543.75% | -8139.49% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 286.57% | 184.73% | 150.46% | 156.90% | 150.36% |
| Return on Assets (ROA) | -130.27% | -162.58% | -143.21% | -434.24% | -669.45% |
| Return on Equity (ROE) | 6.50% | 8.70% | 9.08% | 14.65% | 16.97% |
| Return on Capital Employed (ROCE) | 2.27% | 4.71% | 6.04% | 9.33% | 11.28% |
| Return on Invested Capital (ROIC) | 15.99% | 26.41% | 16.78% | 38.73% | 49.02% |
| Return on Tangible Assets | -130.27% | -162.58% | -143.21% | -434.24% | -669.45% |
| Earnings Yield | -14.60% | -14.84% | -6.41% | -22.71% | -6.54% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 4.22 | 0.23 | 0.00 |
| Payables Turnover | 176.66 | 32.15 | 221.44 | 3.05 | 0.00 |
| Inventory Turnover | 0.20 | 0.41 | 0.52 | 0.12 | 0.00 |
| Fixed Asset Turnover | 2.63 | 1.17 | 0.89 | 0.12 | 0.00 |
| Asset Turnover | 0.68 | 0.38 | 0.26 | 0.05 | 0.00 |
| Working Capital Turnover Ratio | -0.03 | -0.02 | -0.02 | -0.00 | 0.00 |
| Cash Conversion Cycle | 1841.01 | 873.27 | 789.35 | 4518.94 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 86.42 | 1558.29 | 0.00 |
| Days of Inventory Outstanding | 1843.07 | 884.62 | 704.59 | 3080.44 | 0.00 |
| Days of Payables Outstanding | 2.07 | 11.35 | 1.65 | 119.79 | 0.00 |
| Operating Cycle | 1843.07 | 884.62 | 791.00 | 4638.73 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.01 | -0.01 | 0.01 | -0.01 | -0.01 |
| Free Cash Flow Per Share | -0.01 | -0.01 | 0.01 | -0.01 | -0.01 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -16.41 | 21.06 | -40.00 | -12.92 |
| Capital Expenditure Coverage Ratio | 0.00 | -16.41 | 21.06 | -40.00 | -12.92 |
| Operating Cash Flow Coverage Ratio | -0.11 | -0.12 | 0.14 | -0.15 | -0.19 |
| Operating Cash Flow to Sales Ratio | -2.71 | -4.94 | 5.23 | -63.70 | 0.00 |
| Free Cash Flow Yield | -20.81% | -18.25% | 5.87% | -18.22% | -6.16% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -6.85 | -6.74 | -15.61 | -4.40 | -15.28 |
| Price-to-Sales (P/S) Ratio | 13.03 | 28.72 | 84.89 | 358.37 | 0.00 |
| Price-to-Book (P/B) Ratio | -0.44 | -0.59 | -1.42 | -0.64 | -2.59 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.81 | -5.48 | 17.03 | -5.49 | -16.25 |
| Price-to-Operating Cash Flow Ratio | -4.81 | -5.81 | 16.22 | -5.63 | -17.50 |
| Price-to-Earnings Growth (PEG) Ratio | 0.23 | -0.81 | 3.90 | 0.16 | -0.43 |
| Enterprise Value Multiple | -62.27 | -32.03 | -53.17 | -15.12 | -29.68 |
| Enterprise Value | 10.34M | 11.77M | 15.03M | 9.09M | 18.89M |
| EV to EBITDA | -62.27 | -32.03 | -53.17 | -15.12 | -29.68 |
| EV to Sales | 38.14 | 68.75 | 121.62 | 779.67 | 0.00 |
| EV to Free Cash Flow | -14.07 | -13.12 | 24.40 | -11.94 | -21.06 |
| EV to Operating Cash Flow | -14.07 | -13.92 | 23.24 | -12.24 | -22.69 |
| Tangible Book Value Per Share | -0.11 | -0.12 | -0.11 | -0.09 | -0.08 |
| Shareholders’ Equity Per Share | -0.11 | -0.12 | -0.11 | -0.09 | -0.08 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 2.79 | 1.78 | 1.96 | 1.52 | 1.46 |
| Research & Development to Revenue | 0.69 | 1.34 | 1.48 | 22.62 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 2.23 | 27.80 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.42 | 1.16 | -0.96 | 0.78 | 0.87 |
Currency in USD
